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This study aims to investigate the hypoglycaemic and hypocholesterolaemic 
properties of Malaysian cocoa (Theobroma cacao) polyphenols extract in-vivo and 
in-vitro. Cocoa extract (contained 190 - 286 mg total polyphenol per g of extract) 
was prepared from fermented and roasted (140 "C, 20 min) beans by extracting with 
80% ethanol in the ratio of 1 to 10. The total phenolic content was estimated 
according to the Folin-Ciocalteu reagent method. The eluted individual polyphenol 
was monitored by using a normal-phase HPLC. Monomer is the predominant 
polyphenols present in cocoa extract (CE) followed by dimer and tetramer. To study 
the effect of CE on plasma glucose levels and lipid profiles in normal and diabetic 
rats, two different batches of animal (in-vivo) studies were performed. In the first 
batch, rats were given free excess to diet containing CE in the form of powder, while 
in the second batch, rats were force-fed with CE suspended in normal saline daily. 
The CE was given in three dosages (100, 200 and 300 mg per kg body weight) to 
both batches for a period of 4 weeks. The result showed that 100 mgkg and 300 
mgkg CE significantly reduced (p < 0.05) the plasma glucose levels in the diabetic 
rats of both the first and second batch of studies. In the first batch, supplementation 
of 100 mgkg and 300 mglkg CE had significantly reduced (p < 0.05) the level of 
total cholesterol in diabetic rats. In addition, 100, 200 and 300 mgkg CE diets had 
significantly lowered (p < 0.05) the total triglycerides. Interestingly, this study found 
that plasma HDL-cholesterol had increased significantly (p < 0.05) in diabetic rats 
fed with 200 mgkg CE, while the LDL-cholesterol had decreased significantly (p < 
0.05) in group treated with 100 mgkg CE. In the second batch, plasma cholesterol, 
HDL-cholesterol and LDL-cholesterol levels showed no siginificant difference in 
both normal and diabetic rats. Meanwhile, there was a significant decrease (p < 0.05) 
in plasma triglyceride level in diabetic rats. In another study, rats were pretreated 
with CE to investigate the protective effect of CE against streptozotocin diabetogenic 
action. In 200 mglkg CE pretreated rats, there was a 163% increase in plasma 
glucose levels, compared with a 226% increase in diabetic control rats. There were 
no protective effects on plasma lipid profiles in CE pretreated rats. Results also 
exhibited CE could normalize the body weight loss caused by STZ. BRIN-BD11 cell 
lines (in-vitro) were used to evaluate the effect of CE on insulin secretion. This in- 
vitro study demonstrated that CE at a concentration of 0.1 mglrnl significantly 
increase (p < 0.05) insulin secretion compared to control. In conclusion, the study 
shows that Malaysian cocoa polyphenol extract may possess potential 
hypoglycaernic and hypochlosterolaernic properties. Further studies are needed to 
elucidate the exact mechanism by which polyphenols present in CE can lower the 
plasma glucose levels and improved lipid profiles in diabetic rats, and stimulate 
insulin secretion in BRIN-BDl1 cell lines. 
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Kajian ini bertujuan untuk mengkaji ciri-ciri hipoglisemik dan hipokolesterolemik 
ekstrak polifenol koko Malaysia (Theobroma cacao) secara in-vivo dan in-vitro. 
Ekstrak koko (mengandungi 190 - 286 mg polifenol per g ekstrak) disediakan 
daripada biji koko yang telah difermentasi dan dipanggang (140 "C, 20 min) dengan 
mengekstrak menggunakan 80% etanol berdasarkan nisbah 1 kepada 10. Pengiraan 
jumlah kandungan polifenol menggunakan kaedah Folin-Ciocalteu. Polifenol 
individu ditutdisis dengan menggunitkan f s a  normal HPLC. Moncmw addah 
polifenol yang paling banyak terdapat di dalam CE diikuti oleh dimer dan tetrarner. 
Untuk mengkaji kesan CE ke atas paras plasma glukosa dan profil lipid tikus normal 
dan diabetik, dua kumpulan kajian haiwan (in-vivo) telah dijalankan. Dalam kajian 
kumpulan pertama, tikus tersebut bebas untuk mengambil makanan dalam bentuk 
serbuk yang mengandungi CE, sementara dalam kumpulan kedua, tikus diberi CE 
yang dilarutkan di dalam salin normal secara oral (suapan paksa). CE diberi dalam 
tiga dos (100, 200 dan 300 mg per kg berat badan), dan diberi kepada kedua-dua 
kumpulan selama 4 rninggu. Keputusan menunjukkan 100 mgkg dan 300 mgkg CE 
menurunkan paras plasma glukosa secara signifikan (p < 0.05) di dalarn kedua-dua 
kumpulan. Di dalam kajian kumpulan pertama, pemberian 100 mgkg dan 300 mgkg 
CE menurunkan paras plasma kolesterol secara signifikan (p < 0.05) di dalam tikus 
diabetik. Tambahan pula, 100, 200 dan 300 mgkg diet CE menurunkan kandungan 
trigliserida secara signifikan (p < 0.05). Kajian ini juga mendapati plasma HDL- 
kolesterol meningkat secara signifikan (p < 0.05) di dalam tikus diabetik yang diberi 
200 mgkg CE, sementara LDL-kolesterol menurun secara signifikan di dalam tikus 
diberi 200 mgkg CE. Di dalam kajian kumpulan kedua, paras plasma kolesterol, 
HDL-kolesterol dan LDL-kolesterol tidak menunjukkan perubahan yang signifikan 
di dalam tikus normal dan diabetik. Sementara itu, terdapat penurunan signifikan (p 
< 0.05) di dalam paras plasma trigliserida tikus diabetik. Untuk mengkaji kesan 
perlindungan CE melawan tindakan diabetogenik STZ, tikus diberi CE terlebih 
dahulu sebelum suntikan STZ. Tikus yang terlebih dahulu diberi 200 mgkg CE, 
didapati terdapat peningkatan 163% paras plasma glukosa, berbanding dengan 
peningkatan 226% di dalam tikus kontrol diabetik. Tiada kesan perlindungan ke atas 
plasma profil lipid di dalam tikus yang diberi CE terlebih dahulu. Keputusan juga 
mendapati CE berupaya mengnormalkan kehilangan berat badan disebabkan oleh 
STZ. BRIN-BD 11 sel (in-vitro) digunakan untuk menilai kesan CE ke atas rembesan 
insulin. Di dalarn kajian ini menunjukkan CE pada kepekatan 0.1 m g h l  
meningkatkan rembesan insulin secara signifikan (p < 0.05) berbanding kontrol. 
Secara kesimpulan, kajian ini menunjukkan ekstrak polifenol koko Malaysia 
kemungkinan mempunyai potensi ciri-ciri hipoglisemik dan hipokolesterolemik. 
Kajian selanjutnya diperlukan untuk menerangkan mekanisme keupayaan polifenol 
daripada CE dalam menurunkan paras plasma glukosa dan memperbaiki profil lipid 
di dalam tikus diabetik, dan merangsang rembesan insulin di dalam BRIN-BDll sel. 
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CHAPTER I 
INTRODUCTION 
Diabetes mellitus is a serious and costly disease which is becoming increasingly 
common, especially in developing countries. It is a disease with major long-term 
implications, not only on the health and well-being of the affected individuals, but 
also on the costs incurred by the government. For example in Canada, the annual 
estimated cost of treating patients with diabetes mellitus is 9 billion dollars, while in 
the United States it is estimated to be near 132 billion dollars in 2002 in medical 
expenditures and lost productivity (Dawson et al., 2002; ADA, 2003). There are no 
available statistics on the cost of treating diabetic patients in Malaysia, but WHO 
(2002) estimated that direct health care costs of diabetic patients range from 2.5% to 
15% of total annual budget, depending on local diabetes prevalence and the 
effectiveness of the treatment available. 
In the latest WHO estimation (WHO, 2004), there are over 171 million people 
worldwide who are afflicted with diabetes mellitus. Diabetic individuals can suffer 
from ketoacidosis, a serious acute complication, as well as chronic complications 
that affect essentially every organ system in the body, among them cardiovascular 
diseases, stroke, blindness, kidney failure, neurological dysfunction, necrosis and 
gangrene. 
The discovery of insulin in 1921 revolutionized diabetes treatment and greatly 
reduced the acute complication of diabetes mellitus. As diabetics began to live longer, 
however, the chronic complications have taken over as the principal cause of 
morbidity and mortality. Advances in our understanding of the pathophysiology of 
diabetes in the past several decades have produced significant improvements in 
therapy. There are two main types of diabetes mellitus: type 1, which was previously 
known as insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes 
mellitus, and is caused by absolute insulin deficiency; and type 2 or non-insulin 
dependent diabetes mellitus (NIDDM) or maturity-onset diabetes mellitus, which 
occurs mainly in adulthood, is often associated with obesity, and results from a 
combination of insulin resistance and @-cell dysfunction, leading to relative insulin 
deficiency (Kahn, 2003). 
Although diabetes mellitus is a non-communicable disease, it is considered one of 
the five leading causes of death in the world. Recently, the search for appropriate 
hypoglycaernic agents has focused on plants used in traditional medicine, partly 
because of leads provided by traditional medicine to natural products that may be 
better treatments than currently used drugs (Lu et al., 2002; Jang et al., 2003; Kar et 
al., 2003). Drug such as sulphonylureas, lead to higher risk of hypoglycaemia, and 
metformin brings a higher risk of lactic acidosis (Shenfield, 2001). Due to the side 
effects of these drugs, many researches have been conducting studies on natural 
products derived from plants with potential antidiabetic activities (Kamtchouing et 
al., 1998; Jayakar and Suresh, 2003; Ladeji et al., 2003; Maghrani et al., 2003). 
Besides the traditional medicinal plants, cocoa beans were thought to have fearsome 
magical powers by the Mayas and were carefully used by priests in rituals, religious 
ceremonies and healings. The Mayas used cocoa medicinally as a treatment for 
fever, coughs and to help dispel even discomfort during pregnancy. After the 1 6 ~  
century conquest of Central America by Spain, Cortes introduced cocoa to Europe, 
where it was typically viewed as a healthy and nutritious beverage (Dillinger et al., 
2000). Therefore, to evaluate the hypoglycaemic and hypocholesterolaemic effect of 
cocoa beans, this study was designed to test its effectiveness in reducing 
hyperglycaemia and hypercholesterolaemia based on in-vivo (animal) and in-vitro 
studies. 
Malaysian is one of the main cocoa-based products producer in the world and the 
biggest in Asia. However, our local cocoa-based markets are more prefer other cocoa 
beans (West African and Ghanian beans) due to some weaknesses in Malaysian 
beans quality (low cocoa aroma, astringent and bitter taste). One of the factors 
causing this is believed to be due to the high amount of the polyphenol substances. 
Recently, polyphenols have become intense focus of research interest because of 
their antioxidant capacity and possible beneficial health effects. Thus, this study uses 
the superiority of Malaysian beans in order to evaluate its potential beneficial health 
effects especially in diabetes mellitus. 
Historically, animal models have been used to screen out extracts, pure compounds 
or drugs, and obtain information to help in understanding health disorders and to test 
the safety of these materials before putting them on the market. Scientists from 
around the world usually use animal model to study the way the disease progresses, 
and factors that are important to the disease process. Animal models are also used to 
study the treatment of diseases before it can be applied to humans. Usually, after 
animal study is performed, it will be followed up with additional laboratory studies 
using cell culture (in-vitro model) for result confirmation. 
Streptozotocin (STZ)-induced hyperglycaemia in rats have been described as a 
useful experimental model to study the activity of antidiabetic agents with or without 
insulin (LeDoux et al., 1986). A range of STZ doses provide a wider range compared 
to alloxan, as an inducer of hyperglycaemia. The frequently-used single intravenous 
or intraperitoneal dose in adult rats to induce diabetes mellitus type 1 is between 40 
and 60 mglkg body weight (Pepato et al., 2001; McAnuff et al., 2002), but higher 
doses are also used (Ladeji et al., 2003). In this study, two different batches of 
animal fed with cocoa extract (CE) via two different techniques were used: (1) CE 
mixed with purified diet, powder form and (2) forced-fed CE suspended in liquid 
solution. The aim of the experiment was to study the hypoglycaemic and 
hypocholesterolaemic effect of Malaysian cocoa extract. The rationale of using two 
different feeding techniques is to ensure the results derived from the second batch 
(force-feeding) supported the findings of the first batch (free excess to diet 
containing CE). In addition, for the first batch study, actual amount of food intake 
cannot be measured due to a lot of food powder being spilled. Furthermore, the food 
intake varied from one rat to another and because of that, it is difficult to measure the 
exact polyphenol intake of the rats. Therefore, in order to make sure the exact doses 
of CE were taken by the rats, force-feeding using intubation needle (second batch) 
was designed to improve the effectiveness of this first batch design. 
The search for a safer and more effective compound in protecting the p-cells from 
inflammatory destruction by ST2 is still being done. Several compounds such as 
metallothionein, nicotinamide, glucose and (-)epicatechin have been reported to 
inhibit the diabetonic action of streptozotocin or alloxan (Kamtchouing et al., 1998; 
Yang and Cherian, 1994). Khalid (2002) found that palm Vitee (palm oil Vitamin E) 
has a protective property against the toxic inflammation caused by single dose STZ 
administration. Thus, this study was also designed to evaluate the protective action 
of CE against the destruction of insulin-producing p-cells of the pancreas in STZ- 
induced diabetic rats. 
To understand the possible mechanisms by which CE improves hyperglycaemia, the 
effect of CE on insulin secretion by insulin-secreting cells was investigated. Insulin- 
secreting cell lines have provided useful systems for the study of pancreatic P-cell 
function. The BRIN-BD1 1 cell line is a clonal glucose responsive insulin-secreting 
cell line which is responsive to a range of pharmacological modulators of insulin 
. - 
secretion. Most of the available cell lines exhibit glucose insensitivity or moderate 
responsiveness to sub-physiological concentrations of glucose (Newgard, 1994). 
Thus, this study utilizes this cell line superiority to examine the effects of CE upon 
insulin secretion alone without the presence of glucose. 
